Study population and study sites:~The study is carried out in about 30 private practices or clinics in Germany that regularly carry out SARS-CoV-2 PCR tests and treat COVID-19 patients.~Adult close contact persons of newly diagnosed COVID-19 patients living in the same household are considered for participation.~Study duration and assessment:~The study will last 14 days, in which the following study-specific measures will be undertaken:~Documentation of demographics (age, gender, ethnicity, height and weight, degree of relationship to the COVID-19 patient)~Documentation of current comorbidities~Documentation of current medical accompanying measures~Documentation of the general condition~Vital signs~COVID-19 symptoms~SARS-CoV-2 PCR test: Only for medical confirmation of the presence of COVID-19 symptoms during an unplanned COVID-19 visit or final visit.~Subject diary (daily measurement of body temperature, contact intensity with the index person)~Pregnancy test in women of childbearing potential~Objectives:~Primary Objective: To demonstrate the efficacy of ivermectin in the COVID-19 post-exposure prophylaxis of adult contact persons living in the household of a person suffering from COVID-19 (index person)~Secondary objectives:~To demonstrate the safety of ivermectin in the COVID-19 post-exposure prophylaxis of adult contact persons living in the household of a person suffering from COVID-19 (index person)~To determine the severity of the symptoms of subjects suffering from COVID-19 during the study period and the comparison between the ivermectin and the placebo group.~IMP: Driponin® is an approved drug with the active ingredient Ivermectin, used to treat parasitic infections. One tablet Driponin® contains 3 mg Ivermectin. As part of the clinical trial, the medicinal product will be examined with regard to indication, dosage and application schedule deviating from the intended purpose and the package insert.
The Prevent-COVID study is a prospective, multicenter, randomized, two-armed, placebo-controlled, double-blind, interventional study in which the efficacy and safety of ivermectin in COVID-19 post-exposure prophylaxis (PEP) is examined in adult, close family contacts living in the household of a subject suffering from COVID-19.